The topics encompassed central carbon metabolism in cancer, non-small-cell lung cancer, the prolactin signalling pathway, resistance to EGFR tyrosine kinase inhibitors, melanoma, chronic myeloid leukaemia, prostate cancer, ErbB signaling pathway, endocrine resistance, colorectal cancer, the thyroid hormone signalling pathway, and breast cancer. This evidence concerns the gene PRL and prostate carcinoma.